Chang Gloria Y, Yopp Adam C
Department of Surgery, Division of Surgical Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Department of Surgery, Division of Surgical Oncology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA.
Surg Oncol Clin N Am. 2024 Jan;33(1):99-109. doi: 10.1016/j.soc.2023.07.004. Epub 2023 Aug 29.
Hepatic resection is one of the mainstays of curative therapy for hepatocellular carcinoma (HCC). The appropriate selection of resectable candidates requires careful consideration of a multitude of factors including tumor burden (size and number of nodules, presence of vascular involvement, extrahepatic spread), patient factors (performance status, underlying liver function), and availability of other therapies (access to transplantation, interventional procedures, immunotherapies). Historically, hepatic resection for HCC has been reserved for patients with solitary tumors without vascular invasion. However, in well-selected patients HCC tumors multifocal in nature or with vascular invasion should be considered for hepatic resection.
肝切除术是肝细胞癌（HCC）根治性治疗的主要手段之一。对于可切除患者的恰当选择需要仔细考虑众多因素，包括肿瘤负荷（结节大小和数量、血管侵犯情况、肝外转移）、患者因素（体能状态、基础肝功能）以及其他治疗方法的可及性（肝移植、介入治疗、免疫治疗）。从历史上看，HCC肝切除术一直只适用于无血管侵犯的单发肿瘤患者。然而，对于经过精心挑选的患者，本质上为多灶性或有血管侵犯的HCC肿瘤也应考虑行肝切除术。
